The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019.


PHILADELPHIA — Levodopa inhalation powder (Inbrija™, Acorda Therapeutics) has demonstrated efficacy among individuals with Parkinson disease in achieving an ON state during OFF periods, as well as in gaining more dyskinesia-free ON time and lowering the daily amount of OFF time, according to research presented at the 2019 American Academy of Neurology Annual Meeting, held May 4-10, 2019, in Philadelphia, Pennsylvania.

Related Articles

This extension study of the original SPAN-PD study included 161 individuals randomly assigned to levodopa inhalation powder 60 mg and 164 randomly assigned to levodopa inhalation powder 84 mg for OFF periods, all of whom were blinded to dosage. All participants maintained their regular regimens of oral carbidopa and levodopa. An in-clinic assessment was performed to examine efficacy through the presence of an ON state within 1 hour of dose, as well as through the changes in daily ON and OFF-without-dyskinesia times. Participants also recorded information in a home diary.

At the 12-month mark, an ON state was achieved within 1 hour by 68.4% of those in the levodopa inhalation powder 60 mg group and 73.0% of those in the levodopa inhalation powder 84 mg group. These values did not differ significantly from those found at 1 month. Mean changes in daily OFF time from baseline showed improvement between 1 month (-0.33 hours, 60 mg; -0.55 hours, 84 mg) and 12 months (-0.70 hours, 60 mg; -0.88 hours, 84 mg). Mean change in daily ON time without dyskinesia also showed improvement between 1 month (+0.23 hours, 60 mg; +0.18 hours, 84 mg) and 12 months (+0.32 hours, 60 mg; +0.40 hours, 84 mg).

The study researchers conclude that “[levodopa inhalation powder] maintained its efficacy in achieving an ON state in patients experiencing OFF periods, and showed improved efficacy in decreasing daily OFF time and increasing ON time without dyskinesia over 12 months.”

Disclosure: All authors disclosed affiliations with pharmaceutical companies. See the reference for complete disclosure information.

For more coverage of AAN 2019, click here.

Reference

Farbman ES, Lew M, Waters CH, Hauser RA, Klingler M, Oh C. Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease. Presented at: 2019 American Academy of Neurology Annual Meeting; May 4-10, 2019; Philadelphia, PA. Abstract P2.8-048.

This article originally appeared on Neurology Advisor